A new peer-reviewed network meta-analysis published in Expert Review of Endocrinology & Metabolism has directly compared tirzepatide — the active ingredient in Mounjaro and Zepbound — against sleeve gastrectomy and other obesity pharmacotherapies for weight loss. The research gives patients and clinicians a clearer picture of where the medication stands relative to bariatric surgery.
What the Researchers Did
The study was a systematic review and network meta-analysis of randomized controlled trials. Researchers searched three major medical databases — MEDLINE, EMBASE, and Cochrane CENTRAL — for trials published between 2014 and 2024. The analysis included studies comparing sleeve gastrectomy, tirzepatide, and other pharmacological treatments for obesity, allowing indirect comparisons across treatments even when head-to-head trials don't exist.
Tirzepatide works by activating two hormone receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic peptide (GIP) receptor. This dual mechanism distinguishes it from GLP-1-only medications like semaglutide (Ozempic, Wegovy).
Why This Research Matters for Patients
For people living with obesity, the question of medication versus surgery is one of the most significant decisions they may face. Sleeve gastrectomy is an established and effective procedure, but it carries surgical risks, requires a major lifestyle adjustment, and is not suitable for everyone. The emergence of highly effective GLP-1 and dual GIP/GLP-1 medications has prompted researchers to ask how these newer options stack up against surgical intervention.
A network meta-analysis is particularly valuable here because it can synthesize evidence across multiple treatments simultaneously — giving a broader comparative picture than any single trial can provide.
Key takeaway: This is among the first systematic analyses to place tirzepatide directly alongside sleeve gastrectomy in a rigorous, multi-database comparison, marking an important step in understanding whether medication could serve as a genuine alternative or complement to bariatric surgery for some patients.
What Patients Should Know Right Now
While the full results of the study go beyond the available abstract, the research context is meaningful for anyone currently on or considering tirzepatide:
- Tirzepatide (Zepbound) is FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
- Sleeve gastrectomy remains a well-established intervention, and this study does not suggest patients should abandon surgical consultations — rather, it adds to the evidence base that helps inform those conversations.
- Individual factors like medical history, comorbidities, prior treatment attempts, and personal preference all play a role in determining the right approach.
What to Watch Next
As the full publication becomes more widely available, expect clinicians and obesity medicine specialists to discuss its findings in greater detail. Research comparing GLP-1 and dual GIP/GLP-1 medications to surgical options is a fast-moving area, and additional trials are ongoing. Patients interested in understanding their full range of options should look for updated clinical guidelines as this evidence continues to accumulate.
Frequently Asked Questions
This study adds an important piece to an evolving conversation about obesity treatment options, but every patient's situation is unique. Speak with your prescriber or an obesity medicine specialist to understand how the latest research applies to your own health goals and medical history.
- Peer-reviewed journal article, 'Comparison of pharmacotherapies for obesity with sleeve gastrectomy: a network meta-analysis and systematic review,' Expert Review of Endocrinology & Metabolism, 2024.